SUMMARY During the last seven years 65 patients with Gilles de la Tourette's syndrome have been treated. Pimozide was used as the preferred drug because of our experience of treating other hyperkinesias which indicated fewer side-effects than with haloperidol. Of the 65 patients with Gilles de la Tourette's syndrome, 59 were treated with pimozide alone or in combination with tetrabenazine or clonidine. The dose ranges of pimozide were 095-9 mg per day. Eighty-one percent experienced a good clinical response without side-effects. The side-effects seen in our patients were sedation, gain in weight, depression, pseudoparkinsonism and akathisia; acute dystonic reactions, blurred vision, slurred speech and xerostomia did not occur. No cases of tardive dyskinesia were seen.
Treatment of Gilles de la Tourette's syndrome has been difficult and disappointing. In 1961 a marked reduction of motor and vocal tics in a case of Gilles de la Tourette's syndrome was reported after treatment with haloperidol.' These results were soon confirmed by other investigators,2 5who found that such treatment had beneficial effects in up to 89% of patients. Phenothiazines also have been tried, but had a lesser suppressing effect on tiCS6 7 and haloperidol has therefore been, and in many centres still is, considered the drug of choice. However, treatment with haloperidol is accompanied by side-effects in many patients.
We have therefore looked for other agents with similar therapeutic action, but with fewer side-effects. Pimozide, a diphenylbutylpiperidine, is one of these; like haloperidol it has a strong blocking effect upon the postsynaptic dopamine receptor, but in several trials on different hyperkinetic diseases, it was found to have fewer side-effects. 8 -16 In our treatment of Gilles de la Tourette's syndrome over the last 7 years we have therefore used pimozide as the preferred drug. The aim of the present study has been to investigate the clinical features of Danish Gilles de la Tourette's syndrome patients and to evaluate the effect of treatment.
Material and method
Sixty-five patients with Gilles de la Tourette's syndrome, 49 males (75%) and 16 females (25%) were followed from 6-84 months in the out-patients clinic. The diagnosis was made by history and clinical impression according to the criteria of Shapiro et al.5
The age of the patients at the time of the investigation, the age at onset and at the time of diagnosis, the average duration of the disease, and the average interval from onset to diagnosis are shown in table 1. In 38 (58%) of the patients muscular and/or vocal tics were present in the other close family members; of these, 21 (32%) had first degree relatives with tics. There were four Gilles de la Tourette's families represented by eight patients.
Eight (12%) of the patients had delayed development of speech. Twelve (18%) of the patients had a stammer. Of these eight still stammer. In eight (12%) of the patients birth complications such as prematurity and prolonged birth were reported. Two of these patients are intellectually retarded. Two of the patients had neonatal jaundice, which did not require treatment.
The severity of their illness, rated by two of the authors on a 4-point scale from mild to severe according to the criteria given by Shapiro et al,5 was mild in two (3%), moderate in 23 (35%), marked in 28 (43%) and severe in 12 (18%).
The number of the patients with motor and vocal tics at onset and at the time of the investigation is seen in A few patients failed to respond adequately to this regimen. These patients were treated with clonidine in low doses (0 075-0225 mg per day) initially in monotherapy and later in combination with pimozide. 794 defect in the right temporo-parietal-region. Two patients had asymmetry of the ventricles and one patient had slight cortical atrophy.
EEG
Of the 27 EEGs performed elsewhere, 15 were normal, nine were diffusely abnormal in a mild to moderate degree and three were abnormal to a severe degree but without local abnormality.
Discussion
The sex distribution, the age at onset and the interval from onset to diagnosis are in accordance with previously reported series.5 Rating the severity according to criteria given by Shapiro' showed fewer mild cases in our group and rather more patients with marked and severe symptoms, which could be due to the young age of our patients. The more severe cases are referred to us, while the mild cases still are undiagnosed. Fifty-eight per cent of the patients had a family member with tics and in 32% the relative with tics was of first degree; this is significantly higher than the previously reported 40%.1 Seventy-two per cent of the patients showed muscular tics as initial symptom, whereas in 37% vocal tics were the initial symptoms indicating multiple tics at onset in some of the patients. (These figures may be distorted by the patients or their family because of problems with recollection of symptomatology at onset). None of the patients had coprolalia as the first symptom. Coprolalia was seen in 26% of our patients. Shapiro'7 found coprolalia in 33% of his patients.
The list of examples of obscenities given is not complete owing to reluctance of our patients to mention their actual swear words. Echolalia was found in 34% of the patients, which is in accordance with other reports5 while echopraxia was found in a higher proportion. Taken as a whole the patients in our group do not differ significantly from those of other series. Only one of our patients takes more than 8 mg pimozide per day in periods of aggravation of symptoms. Six of the patients are being treated with 3-8 mg pimozide per day; all the other patients on pimozide therapy are being treated with doses from 0 5-3 mg per day. The doses used are clearly below those employed in other series.16 1819 and may explain why we did not see acute dystonic reactions and why Parkinsonism was seen in only one of our patients. Treatment with anticholinergics has only been necessary in one patient, a case of restless legs.
As pointed out by other authors'8 it is important to start with a very low dose (0.5-1 mg per day) and to raise the dose very slowly. Children were given one dose in the morning and one in the afternoon, but no evening dose. The same regimen can be used with Regeur, Pakkenberg, Fog, Pakkenberg adults. It is our experience that the treatment response to an increase of pimozide above 8 mg per day is very poor, and it is more advisable to combine pimozide with drugs with a different site of action such as tetrabenazine or clonidine than to increase the dose in patients whose symptoms cannot be controlled on 8 mg.
In table 4 only the periods in which the patients received medication was recorded and did not include the drug-free intervals. We encourage our patients to decrease and, if possible, to discontinue medication altogether in the good periods of their illness. So far none of our patients have developed long-term sideeffects, that is tardive dyskinesia. We believe that the strict regimen with the low doses and drug-free intervals is the best way to avoid these.
The superiority of pimozide to haloperidol may be related to its more specific blocking of dopamine and to absence of norepinephrine antagonism.202'
In conclusion we treat our Gilles de la Tourette's syndrome patients with mild to moderate symptoms beneficially, but some of the patients with severe symptoms still represent a problem in periods with aggravation of symptoms. In our experience, pimozide is the drug of choice in the treatment of Gilles de la Tourette's syndrome, because it induces fewer side-effects than haloperidol. Like other neuroleptics, however, pimozide implies a risk of long-term adverse side-effects (tardive dyskinesia). More effective therapeutic agents with less adverse side-effects are still needed.
